We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.
- Authors
Cao, Z-X; Liu, J-J; Zheng, R-L; Yang, J; Zhong, L; Xu, Y; Wang, L-J; Zhang, C-H; Wang, B-L; Ma, S; Wang, Z-R; Xie, H-Z; Wei, Y-Q; Yang, S-Y
- Abstract
A letter to the editor is presented which discusses the preclinical effectiveness of the multikinase inhibitor, SKLB1028 in acute myeloid leukemia (AML).
- Subjects
LETTERS to the editor; KINASE inhibitors; ACUTE myeloid leukemia treatment
- Publication
Leukemia (08876924), 2012, Vol 26, Issue 8, p1892
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2012.67